Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.

Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.

Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.

Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.

compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters). The percentage of strongly PD-L1 positive participants who experienced a CR or PR is presented.

Adverse events are defined as any adverse medical events that occur in the participants taking the drugs and do not necessarily have a causal relationship with the treatment.

PFS was defined as the time from the first day of study treatment to the first documented disease progression per irRC or death due to any cause, whichever occurred first.